Southern Medical University scientists have reported the discovery and preclinical characterization of novel microtubule-inhibiting agents being developed for the treatment of cancer. Discovery of ...
First approved in 2020, first-in-class microtubule inhibitor Klisyri (tirbanibulin 1%) reached the market in early 2021, joining a short list of therapies in the US that are available for AK ...
The company’s lead compound ricolinostat is an oral, selective inhibitor of the microtubule-modifying enzyme histone deacetylase 6 (HDAC6). With first-in-class potential, ricolinostat is ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback